Heart involvement in patients with myotonic dystrophy type 2
Tóm tắt
Myotonic dystrophy type 2 (DM2) is a slowly progressive, autosomal-dominant disease. This is a multisystemic disorder that affects the heart, which is one of the main causes of morbidity and mortality in DM2. The aim of the study was to define cardiac impairments in patients with DM2 and its association with sociodemographic and clinical features of patients. This retrospective study comprised 62 adult patients with DM2 hospitalized at the Neurology Clinic, Clinical Center of Serbia from 2013 until 2018, who underwent electrocardiography (ECG) and echocardiography examinations. Hypertension was observed in 42% of DM2 patients. One-fifth of DM2 patients had bradycardia, while other conduction and rhythm impairments were rare. Only one patient had a pacemaker implanted because of the first degree AV block associated with incomplete left bundle branch block. Echocardiography showed diastolic dysfunction of the left ventricle in 44% of patients, while systolic dysfunction was found in only 4%. Cardiomyopathy was observed in 18% of patients, of whom three-fourth had dilated type. Cardiac conduction and rhythm defects are relatively rare in DM2, while diastolic dysfunction is common. This suggests that regular ECG and echocardiography screening is needed in DM2. Adequate therapy should be introduced in patients with DM2 on time to reduce the frequency of heart complications and to prevent premature death.
Tài liệu tham khảo
Finsterer J (2002) Myotonic dystrophy type 2. Eur J Neurol 9(5):441–447
Johnson NE, Heatwole CR (2012) Myotonic dystrophy: from bench to bedside. Semin Neurol 32(3):246–254
Feingold B, Mahle WT, Auerbach S, Clemens P, Domenighetti AA, Jefferies JL et al (2017) Circulation. In: Management of cardiac involvement associated with neuromuscular diseases: a scientific statement from the American Heart Association. pp, 1–31
Stojanovic VR, Peric S, Paunic T, Pavlovic S, Cvitan E, Basta I et al (2013) Cardiologic predictors of sudden death in patients with myotonic dystrophy type 1. J Clin Neurosci 20(7):1002–1006
Sansone VA, Brigonzi E, Schoser B, Villani S, Gaeta M, De Ambroggi G et al (2013) The frequency and severity of cardiac involvement in myotonic dystrophy type 2 (DM2): long-term outcomes. Int J Cardiol 168(2):1147–1153
Meola G, Cardani R (2015) Myotonic dystrophies: an update on clinical aspects, genetic, pathology, and molecular pathomechanisms. Biochem Biophys Acta 1852:594–606
Wahbi K, Meune C, Bécane HM, Laforêt P, Bassez G, Lazarus A et al (2009) Left ventricular dysfunction and cardiac arrhythmias are frequent in type 2 myotonic dystrophy: a case control study. Neuromuscul Disord 19(7):468–472
Choudhary P, Nandakumar R, Greig H, Broadhurst P, Dean J, Puranik R et al (2016) Structural and electrical cardiac abnormalities are prevalent in asymptomatic adults with myotonic dystrophy. Heart 102(18):1472–1478
Schara U, Schoser BGH (2006) Myotonic dystrophies type 1 and 2: a summary on current aspects. Semin Pediatr Neurol 13(2):71–79
Udd B, Krahe R (2012) The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol 11(10):891–905
Peric S, Maksimovic R, Banko B, Durdic M, Bjelica B, Bozovic I, Balcik Y, Pesovic J, Savic-Pavicevic D, Rakocevic-Stojanovic V (2017) Magnetic resonance imaging of leg muscles in patients with myotonic dystrophies. J Neurol 264(9):1899–1908
Paunic T, Peric S, Cvitan E, Raspopovic S, Peric M, Mandic Stojmenovic G et al (2017) Routine echocardiography in patients with myotonic dystrophy type 1. J Chinese Med Assoc 80(7):408–412
Vujnic M, Peric S, Popovic S, Raseta N, Ralic V, Dobricic V et al (2015) Metabolic syndrome in patients with myotonic dystrophy type 1. Muscle Nerve 52(2):273–277
Ha AH, Tarnopolsky MA, Bergstra TG, Nair GM, Al-qubbany, Healey JS (2012) Predictors of atrio-ventricular conduction disease, long-term outcomes in patients with myotonic dystrophy types I and II. Pacing Clin Electrophysiol 35(10):1262–1269
Yang G, Sau C, Lai W, Cichon J, Li W (2015) HHS Public Access 344(6188):1173–1178
Montagnese F, Mondello S, Wenninger S, Kress W, Schoser B (2017) Assessing the influence of age and gender on the phenotype of myotonic dystrophy type 2. J Neurol 264(12):2472–2480
Schoser BG, Ricker K, Schneider-Gold C, Hengstenberg C, Dürre J, Bültmann B, Kress W, Day JW, Ranum LP (2004) Sudden cardiac death in myotonic dystrophy type 2. Neurology 63(12):2402–2404
Perfetti A, Greco S, Fasanaro P, Bugiardini E, Cardani R, Garcia-Manteiga JM, Riba M, Cittaro D, Stupka E, Meola G, Martelli F (2014) Genome wide identification of aberrant alternative splicing events in myotonic dystrophy type 2. PLoS One 9(4):e93983
Schmacht L, Traber J, Grieben U, Utz W, Dieringer MA, Kellman P et al (2016) Cardiac involvement in myotonic dystrophy type 2 patients with preserved ejection fraction: Detection by cardiovascular magnetic resonance. Circ Cardiovasc Imaging 9(7):1–11
Romeo V (2012) Myotonic dystrophy type 1 or Steinert’s disease. Adv Exp Med Biol 724:239–257
Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A et al (2006) Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355(3):260–269
Lau JK, Sy RW, Corbett A, Kritharides L (2015) Myotonic dystrophy and the heart: a systematic review of evaluation and management. Int J Cardiol 184(1):600–608
Mace CR, Akbulut O, Kumar AA, Shapiro ND, Derda R, Patton MR et al (2014) NIH Public Access 134(22):1–10